Josephine Clingan, MD
Pain Medicine · Miami, FLNPI 1861627309
Payments from drug & device makers
Across 126 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$225
- Flowonix Medical Incorporated$211
- Scilex Pharmaceuticals Inc.$201
- Collegium Pharmaceutical, Inc.$196
- Nevro Corp.$145
- Boston Scientific$126
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,350100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $225 |
| Flowonix Medical Incorporated | 2 | $211 |
| Scilex Pharmaceuticals Inc. | 10 | $201 |
| Collegium Pharmaceutical, Inc. | 15 | $196 |
| Nevro Corp. | 1 | $145 |
| Boston Scientific | 8 | $126 |
| Averitas Pharma Inc. | 1 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $117 |
| Tersera Therapeutics LLC | 5 | $111 |
| Biohaven Pharmaceuticals, Inc. | 5 | $105 |
| Amgen | 5 | $92 |
| Lilly USA, LLC | 4 | $66 |
| Novartis | 5 | $65 |
| SPR Therapeutics, Inc | 3 | $59 |
| Arbor Pharmaceuticals, Inc. | 2 | $55 |
| Sentynl Therapeutics, Inc. | 4 | $53 |
| Redhill Biopharma Inc. | 4 | $52 |
| Forte Bio-pharma LLC | 2 | $45 |
| Pfizer | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Medtronic(2 entities) | 2 | $37 |
| GRT US Holding, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $23 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| MDD US Operations, LLC | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$145
- Qutenza$119
- Prometra II$112
How this compares
$2,358 in reported general payments places this provider in the 50th percentile of 596 pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 34 | $388 |
| Diclofenac Sodium | 13 | $327 |
| Celecoxib | 18 | $252 |
| Gabapentin | 21 | $155 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Miami
- Abel MurilloMiami$1.6M
- Jeffrey GudinMiami$378K
- Ramon AlegretMiami$69K
- Anand PatelOrmond Beach$20.4M
- Julio PaezClermont$2.3M
- Joseph PergolizziNaples$2.1M
- George MonluxPalm Coast$1.3M
- Ferdinand FormosoJacksonville$1M
- Cesar LassalleOrlando$1M
- Robert GuirguisTampa$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.